evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 8 findings · 1 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 100%High 0 · 0%

Rivastigmine vs placebo

Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Rivastigmine vs placebo

Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to lower physician rated global impression tests (no change or worse compared… compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Behavioural symptoms (change from baseline at 26 weeks measured using various scales) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Rivastigmine vs placebo

Acceptability · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review